Phase 2 N=31 Azacitidine and Lenalidomide for Acute Myeloid Leukemia
Leukemia, Myeloid, Acute
Primary: Phase I Only - Maximum Tolerated Dose (MTD) as Measured by Dose-limiting Toxicities (DLTs) — 1; 0; 0 dose-limiting toxicities
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=45 Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Adult Acute Basophilic Leukemia · Adult Acute Eosinophilic Leukemia · Adult Acute Megakaryoblastic Leukemia (M7)
Primary: Complete Response — 45 participants
Phase 2 N=46 Prospective Study of Mylotarg and G-CSF in Acute Myeloid Leukemia Treatment
Novo Acute Myeloid Leukemia
Primary: Complete Remission of the Disease — NA; 18; 16; NA Participants
Phase 2 N=172 Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome · Adult Acute Minimally Differentiated Myeloid Leukemia (M0) · Adult Acute Monoblastic Leukemia (M5a)
Primary: Complete Response Rate — 76; 24 participants
Phase 2 N=40 Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia
AML
Primary: Complete Response Rate — 19 Participants
Phase 2 N=74 Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome · Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Primary: Complete Response — 24; 29 participants
Phase 2 N=52 AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia
Leukemia, Myeloid, Acute
Primary: Phase I Only: Optimal Dose of AMD3100 Plus MEC in Patients With Relapsed or Refractory AML — 240 mcg/kg
Phase 2 N=20 Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia
Acute Myeloid Leukemia · Myelodysplastic Syndrome · Chronic Myeloid Leukemia
Primary: Treatment Related Mortality — 0; 0; 0; 0 participants
Phase 2 N=151 Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
Leukemia · AML · MDS
Primary: Participants With a Complete Response — 34 Participants
Phase 2 N=37 Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia
Acute Myeloid Leukemia
Primary: Percentage of Participants With Complete Remission or Complete Remission With Incomplete Recovery Blood Counts — 11 percentage of participants
Phase 2 N=42 Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML
Acute Myeloid Leukemia
Primary: Number of Participants That Achieved Complete Remission — 20 Participants
Phase 2 N=199 Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Acute Biphenotypic Leukemia · de Novo Myelodysplastic Syndrome · Previously Treated Myelodysplastic Syndrome
Primary: Number of Participants With Dose Limiting Toxicities of Mitoxantrone (Phase I, Dose Level 4) — 1; 2 Participants
Phase 2 N=41 Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia
Adult Acute Basophilic Leukemia · Adult Acute Eosinophilic Leukemia · Adult Acute Megakaryoblastic Leukemia (M7)
Primary: Complete Response — 11 percentage of participants
Phase 2 N=27 Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia
Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0) · Adult Acute Monoblastic Leukemia (M5a)
Primary: Inhibition of NF-kB Target Transcripts and/or Inhibition of Drug Efflux in at Least 50% of Patients — 13; 14 Participants — p=<.05
Phase 2 N=25 Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia
Acute Myelogenous Leukemia
Primary: Progression Free Survival — 21 days
Phase 1 N=17 A Study of LAM-003 in Patients With Acute Myeloid Leukemia
Oncology · Acute Myeloid Leukemia
Primary: Maximum Tolerated Dose (MTD) — 0; 0; 0; 0 DLTs
N/A N=26 Low Dose Melphalan and Bortezomib for AML and High-Risk MDS
Acute Myelogenous Leukemia · Myelodysplastic Syndromes
Primary: Response Rate of the Combination of Bortezomib and Melphalan in Patients With AML and High-risk MDS. — 5; 2 participants
Phase 2 N=73 Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia · Secondary Acute Myeloid Leukemia · Therapy-Related Acute Myeloid Leukemia
Primary: Rate of Complete Remission and Mortality in the Entire Cohort of Older Patients — 21.9; 52.0 percentage of subjects
Phase 3 N=256 Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Disorder Related to Bone Marrow Transplantation · Leukemia · Transplantation Infection
Primary: Progression-Free Survival (PFS) — 69; 61 Number of events
Phase 2 N=36 Phase 2 Study of Temozolomide to Treat Poor Risk / Refractory Acute Myeloid Leukemia
Leukemia, Myeloid
Primary: Response Rate (CR + CRi + LFS) — 3; 10 participants
Phase 3 N=223 Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia
Leukemia, Myelocytic, Acute
Primary: Minimal Residual Disease (MRD). — 31; 43; 68; 63 participants — p=.1559
Phase 2 N=59 Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) Induction
Acute Myeloid Leukemia
Primary: Overall Response: Number of Participants With Complete Remission or Complete Remission Without Platelet Recovery — 42; 3 participants
Phase 2 N=84 Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Acute Biphenotypic Leukemia · Acute Myeloid Leukemia · de Novo Myelodysplastic Syndrome
Primary: Phase 1: Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of Mitoxantrone — 18 mg/m^2
Phase 2 N=10 Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia
Relapsed Acute Myeloid Leukemia
Primary: Feasibility of a Novel Combination of Pembrolizumab and Decitabine in Relapsed/Refractory Acute Myeloid Leukemia Participants — 10 Participants
Phase 2 N=66 Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm
Acute Myeloid Leukemia
Primary: Maximum Tolerated Dose (MTD) of Gemtuzumab Ozogamicin (GO) When Added to GCLAM (Phase 1) — NA; NA Participants
Phase 3 N=657 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia
Leukemia
Primary: Overall Survival (Induction Phase) — 15.7; 23.7 months
Phase 3 N=1,645 Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Acute Myeloid Leukemia · Leukemia Cutis · Myeloid Neoplasm
Primary: Event-free Survival (EFS) for Patients Without High Allelic Ratio FLT3/ITD+ Mutations — 45.64; 46.95 percentage of patients
Phase 2 N=196 Busulfan and Fludarabine in Patients With AML and MDS
Leukemia
Primary: Number of Participants With Successful Engraftment — 192 participants
Phase 2 N=27 Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome
Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants With a Response (Complete Remissions (CR), Complete Remissions With Incomplete Platelet Recovery [CRp] and Partial Responses) — 1; 1; 0 participants
Phase 2 N=195 Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression (P05052)
Leukemia, Acute Myeloid · Myelodysplastic Syndrome
Primary: Clinical Response at the End of Temozolomide Induction — 10; 2; 4; 8 participants